Research from technology company RS Components shows that the global biotechnology market is expected to reach $727 billion by 2025.
An analysis of data related to around 2,500 biotech acquisitions also shows how much money has been invested and by which companies.
Following a drop in investment in 2017, 2018 saw record-breaking levels of spending from venture capital funds, with over $150 billion spent on over 125 transactions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze